In Tamoxifen-resistant breast cancer tissues, the GREB1 promoter becomes more methylated via the action of the histone lysine N-methyltransferase EZH2, leading to the epigenetic downregulation of GREB1 [65]. This evidence concerns the gene GREB1 and breast carcinoma.